SCHEMBL3609991

SCHEMBL3609991

Cc1sc(NS(=O)(=O)c2ccc(Cl)cc2)nc1CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.51
GAA P10253 4/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 6/20 0.47
KLKB1 P03952 1/20 0.47
CTSB P07858 1/20 0.47
ELANE P08246 1/20 0.47
LMNA P02545 2/20 0.46
ALOX12 P18054 2/20 0.46
HTT P42858 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
KDM1A O60341 2/20 0.46
MAOA P21397 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3618698 0.87 KMT2A (0.56) KMT2AGAAKDM4EALDH1A1MEN1
SCHEMBL3610154 0.85 AKT1 (0.55) KMT2AGAAKDM4EALDH1A1MEN1
SCHEMBL3251426 0.83 GAA (0.55) KMT2AGAAKDM4EMAPTALDH1A1
SCHEMBL3621819 0.82 HSD11B1 (0.44) KMT2AGAAKDM4EMAPTALDH1A1
SCHEMBL3616804 0.79 HSD11B1 (0.53) GAAALDH1A1HTTKDM1A
SCHEMBL3620639 0.79 HSD11B1 (0.40) KMT2AGAAKDM4EMAPTMEN1
SCHEMBL3616015 0.77 MAPT (0.58) MAPTALOX12
SCHEMBL7147594 0.77 SHMT1 (0.38) KMT2AGAAKDM4EMAPTMEN1
SCHEMBL5912285 0.76 ALDH1A1 (0.81) KMT2AGAAKDM4EMAPTALDH1A1
SCHEMBL5692661 0.76 KMT2A (0.48) KMT2AGAAKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP disclosed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3300/4885GAA 387/4885KDM4E 3184/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 KMT2A 3769/4885GAA 586/4885KDM4E 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.